MyD88 signalling is critical in the development of pancreatic cancer cachexia
Open Access
- 21 January 2019
- journal article
- research article
- Published by Wiley in Journal of Cachexia, Sarcopenia and Muscle
- Vol. 10 (2) , 378-390
Abstract
Background: Up to 80% of pancreatic cancer patients suffer from cachexia, a devastating condition that exacerbates underlying disease, reduces quality of life, and increases treatment complications and mortality. Tumour‐induced inflammation is linked to this multifactorial wasting syndrome, but mechanisms and effective treatments remain elusive. Myeloid differentiation factor (MyD88), a key component of the innate immune system, plays a pivotal role in directing the inflammatory response to various insults. In this study, we tested whether MyD88 signalling is essential in the development of pancreatic cancer cachexia using a robust mouse tumour model.Methods: Sex, age, and body weight‐matched wide type (WT) and MyD88 knockout (MyD88 KO) mice were orthotopically or intraperitoneally implanted with a pancreatic tumour cell line from a syngeneic C57BL/6 KRASG12D/+ P53R172H/+ Pdx‐Cre (KPC) mouse. We observed the effects of MyD88 signalling during pancreatic ductal adenocarcinoma progression and the cachexia development through behavioural, histological, molecular, and survival aspects.Results: Blocking MyD88 signalling greatly ameliorated pancreatic ductal adenocarcinoma‐associated anorexia and fatigue, attenuated lean mass loss, reduced muscle catabolism and atrophy, diminished systemic and central nervous system inflammation, and ultimately improved survival. Our data demonstrate that MyD88 signalling plays a critical role in mediating pancreatic cancer‐induced inflammation that triggers cachexia development and therefore represents a promising therapeutic target.Conclusions: MyD88‐dependent inflammation is crucial in the pathophysiology of pancreatic cancer progression and contributes to high mortality. Our findings implicate the importance of innate immune signalling pathways in pancreatic cancer cachexia and a novel therapeutic target.Keywords
Funding Information
- Brenden-Colson Center for Pancreatic Care
- NCI R01 (CA184324)
This publication has 62 references indexed in Scilit:
- NF-κB–mediated Pax7 dysregulation in the muscle microenvironment promotes cancer cachexiaJournal of Clinical Investigation, 2013
- MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cellsJournal of Experimental Medicine, 2012
- Regulation of Lean Mass, Bone Mass, and Exercise Tolerance by the Central Melanocortin SystemPLOS ONE, 2012
- P‐selectin genotype is associated with the development of cancer cachexiaEMBO Molecular Medicine, 2012
- Central nervous system inflammation induces muscle atrophy via activation of the hypothalamic–pituitary–adrenal axisJournal of Experimental Medicine, 2011
- Pancreatic cancerrelated cachexia: influence on metabolism and correlation to weight loss and pulmonary functionBMC Cancer, 2009
- Regulation of Agouti-Related Protein Messenger Ribonucleic Acid Transcription and Peptide Secretion by Acute and Chronic InflammationEndocrinology, 2008
- TLR signalingCell Death & Differentiation, 2006
- Anatomy and regulation of the central melanocortin systemNature Neuroscience, 2005
- Inflammation and cancerNature, 2002